ArticleClinical lung cancer2025
Outcomes of Patients With Interstitial Lung Disease and Early-Stage Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiotherapy.
Article in Clinical lung cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Radiation-triggered acute exacerbation of progressive fibrotic interstitial lung diseases: 'Are we advancing the frontier or crossing a dangerous line?'Therapeutic advances in respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeTo characterize pulmonary events after stereotactic body radiotherapy (SBRT) in patients with non-small cell lung cancer (NSCLC) and interstitial lung disease (ILD). MATERIALS AND
methodsPatients with Stage I-II NSCLC receiving SBRT from 2004 to 2024 were reviewed. Radiation pneumonitis (RP) and lung infection were scored. Clinical and dosimetric predictors for grade ≥2 RP and pulmonary-related hospitalizations within one year were assessed using univariate analysis and multivariable analysis (MVA), adjusted for the competing risk of death. Overall survival (OS) was evaluated using the log rank test.
resultsOf the 500 patients included, 31 (6.2%) had ILD. Grade ≥2 RP was observed in 5 (16.1%) patients with ILD and 17 (3.6%) patients without ILD (P = .001). Grade ≥3 RP was observed in 2 (6.5%) patients with ILD and 4 (0.9%) patients without ILD (P = .048). No patient had grade 4 or higher RP. On MVA, ILD (HR: 4.44, 95% CI: 1.50-11.32, P = .009) and higher mean lung dose (HR: 1.34, 95% CI: 1.05-1.62, P = .02) predicted for RP. ILD also predicted for pulmonary-related hospitalizations (P < .05) and worse OS (P = .002). The median OS was 36.1 months (range 3.7-76.1 months) in patients with ILD and 54.3 months (range 0.8-150.3 months) in patients without ILD (P <. 001). Two patients with ILD (6.5%) had respiratory deterioration and died within 1 year.
conclusionILD is associated with increased risk of grade ≥2 RP within 1 year of SBRT and poorer OS in patients with NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.